Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Lemos, M. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lemos, M. L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 12, No. 3, 127-129 (2006)
DOI: 10.1177/1078155206069163

Acute reactions to chemotherapy agents

Mário L de Lemos, MSc (Clin Pharm), PharmD

Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B.C., Canada

Acute reactions occur infrequently with chemotherapy agents. However, selected drugs have been known to be associated with severe hyper-sensitivity reactions, infusion reactions and other acute adverse events. The British Columbia Cancer Agency recently updated the list of selected drugs associated with hypersensitivity reactions and the minimum time that immediate physician coverage is needed.

Key Words: antineoplastic agents • drug hypersensitivity • immediate hypersensitivity

References

  • B. C. Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy IV-10: Acute hypersensitivity reactions to chemotherapeutic agents. BC Cancer Agency , January 1998.
  • B. C. Cancer Agency Provincial Systemic Therapy Program. BCCA Protocol Summary for Management of Hypersensitivity Reactions to Chemotherapeutic Agents (SCDRUGRX). BC Cancer Agency , December 2005.
  • Timoney JP, Eagan MM, Sklarin NT. Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy . J Nurs Care Qual 2003; 18: 80-86 .[Medline] [Order article via Infotrieve]
  • Berlex. Campath® product monograph. Berlex , July 2005.
  • Graham ML. Pegaspargase: a review of clinical studies . Adv Drug Deliv Rev 2003; 55: 1293-1302 .[CrossRef][Medline] [Order article via Infotrieve]
  • Bryant R. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration . J Intraven Nurs 2001; 24: 169-173 .[Medline] [Order article via Infotrieve]
  • Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia . Adv Exp Med Biol 1999; 457: 621-629 .[Medline] [Order article via Infotrieve]
  • McEvoy GK ed. AHFS 2002 Drug Information. American Society of Health-System Pharmacists, Inc. , 2004.
  • Alcorn BT. Bleomycin hypersensitivity: a case report . Can J Hosp Pharm 1980; 33: 92-93 .
  • ImClone Systems Incorporated, Bristol-Myers Squibb Company. Erbitux® product monograph. August 2005.
  • Weidmann B, Mulleneisen N, Bojko P, et al. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management . Cancer 1994; 73: 2218-2222 .[CrossRef][Medline] [Order article via Infotrieve]
  • Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin . J Clin Oncol 1999; 17: 1141-1145 .[Abstract/Free Full Text]
  • Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer . Am J Health Syst Pharm 1998; 55: 1777-1791 .[Abstract]
  • Aventis Pharma Inc. Taxotere product monograph. 26 April 1999.
  • Weiss RB. Hypersensitivity reactions . Semin Oncol 1992; 19: 458-477 .[Medline] [Order article via Infotrieve]
  • Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, et al. Hypersensitivity reactions to etoposide . Ann Pharmacother 1996; 30: 367-371 .[Abstract]
  • Sanofi-Synthelabo. Eloxatin: summary of product characteristics. 9 August 2002.
  • Gowda A, Goel R, Berdzik J, et al. Hypersensitivity reactions to oxaliplatin: incidence and management . Oncology (Huntingt) 2004; 18: 1671-1675; discussion 6.
  • Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP) . Br J Cancer 2003; 89: 477-481 .[CrossRef][Medline] [Order article via Infotrieve]
  • Bonosky K, Miller R. Hypersensitivity reactions to oxaliplatin: what nurses need to know . Clin J Oncol Nurs 2005; 9: 325-330 .[CrossRef][Medline] [Order article via Infotrieve]
  • Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule . J Clin Oncol 2002; 20: 1146-1147 .[Free Full Text]
  • Lenz G, Hacker UT, Kern W, et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution . Anticancer Drugs 2003; 14: 731-733 .[CrossRef][Medline] [Order article via Infotrieve]
  • Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin [see comment] . Cancer 2003; 97: 2301-2307 .[CrossRef][Medline] [Order article via Infotrieve]
  • Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin [comment] . Cancer 2004; 100: 211-212 .[CrossRef][Medline] [Order article via Infotrieve]
  • Maindrault-Goebel F, Andre T, Tournigand C, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients . Eur J Cancer 2005; 41: 2262-2267 .[CrossRef][Medline] [Order article via Infotrieve]
  • Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions . Ann Pharmac-other 2000; 34: 1332-1335 .[Abstract]
  • Hoffmann-LaRoche. Rituxan product monograph. 21 June, 2000.
  • McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial . Semin Oncol 1999; 26: 79-87 .[Medline] [Order article via Infotrieve]
  • Onrust SV, Lamb HM, Balfour JA. Rituximab . Drugs 1999; 58: 79-88; discussion 9-90.[CrossRef][Medline] [Order article via Infotrieve]
  • Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with steroid containing chemotherapy can be given safely and substantially reduces resource utilization . Blood 2004; 104-104 : abstract 1407.
  • GlaxoSmithKline Inc. BexxarTM product monograph. 18 August 2005.
  • Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease . J Clin Oncol 1999; 17: 2639-2648 .[Abstract/Free Full Text]
  • Hoffmann-LaRoche. Herceptin product monograph-important drug warning. 4 May, 2000.
  • Hoffmann-LaRoche. Herceptin product monograph. 26 June, 2000.
  • B. C. Cancer Agency Breast Tumour Group. BCCA protocol summary for adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (BRAJTR). BC Cancer Agency , 1 September 2005.
  • B. C. Cancer Agency Breast Tumour Group. BCCA protocol summary for palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) (BRAVTR). BC Cancer Agency , 1 September 2005.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Lemos, M. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lemos, M. L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?